instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
What is the median PFS rate for patients that have undergone Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: What is the median PFS rate for patients that have undergone Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Could you tell me the median Progression-Free Survival rate for patients who received Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
What’s the median rate of PFS in patients treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: What’s the median rate of PFS in patients treated with Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Can you share the median Progression-Free Survival rate in patients who have received Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen? | Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone regimen?
### Response: Patients treated with the Twice-Weekly Carfilzomib 20/27 Mg/M²+Dexamethasone have a median Progression-Free Survival (PFS) rate of 7.6 months, with a 95% CI of (5.8, 9.2). |
Can you tell me the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you tell me the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What’s the median PFS associated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What’s the median PFS associated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Could you provide the median PFS of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Could you provide the median PFS of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
I’d like to know the median PFS of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: I’d like to know the median PFS of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Do you have information on the median PFS of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Do you have information on the median PFS of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median progression-free survival (PFS) for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median progression-free survival (PFS) for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you inform me about the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you inform me about the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
I’m interested in the median PFS of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd). | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: I’m interested in the median PFS of Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd).
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Could you tell me the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Could you tell me the median PFS for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median PFS rate for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median PFS rate for Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median PFS rate in patients who have undergone Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median PFS rate in patients who have undergone Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What’s the median PFS rate for patients receiving Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What’s the median PFS rate for patients receiving Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median PFS rate for patients that have undergone Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median PFS rate for patients that have undergone Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What’s the median rate of PFS in patients treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What’s the median rate of PFS in patients treated with Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone+Daratumumab (D-VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you tell me the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you tell me the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What’s the median PFS associated with Bortezomib+Thalidomide+Dexamethasone (VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What’s the median PFS associated with Bortezomib+Thalidomide+Dexamethasone (VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Could you provide the median PFS of Bortezomib+Thalidomide+Dexamethasone (VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Could you provide the median PFS of Bortezomib+Thalidomide+Dexamethasone (VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
I’d like to know the median PFS of Bortezomib+Thalidomide+Dexamethasone (VTd). | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: I’d like to know the median PFS of Bortezomib+Thalidomide+Dexamethasone (VTd).
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Do you have information on the median PFS of Bortezomib+Thalidomide+Dexamethasone (VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Do you have information on the median PFS of Bortezomib+Thalidomide+Dexamethasone (VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median progression-free survival (PFS) for Bortezomib+Thalidomide+Dexamethasone (VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median progression-free survival (PFS) for Bortezomib+Thalidomide+Dexamethasone (VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you inform me about the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you inform me about the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
I’m interested in the median PFS of Bortezomib+Thalidomide+Dexamethasone (VTd). | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: I’m interested in the median PFS of Bortezomib+Thalidomide+Dexamethasone (VTd).
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Could you tell me the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Could you tell me the median PFS for Bortezomib+Thalidomide+Dexamethasone (VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median PFS rate for Bortezomib+Thalidomide+Dexamethasone (VTd)? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median PFS rate for Bortezomib+Thalidomide+Dexamethasone (VTd)?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median PFS rate in patients who have undergone Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median PFS rate in patients who have undergone Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What’s the median PFS rate for patients receiving Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What’s the median PFS rate for patients receiving Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What is the median PFS rate for patients that have undergone Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What is the median PFS rate for patients that have undergone Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
What’s the median rate of PFS in patients treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: What’s the median rate of PFS in patients treated with Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Thalidomide+Dexamethasone (VTd) regimen? | Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Thalidomide+Dexamethasone (VTd) regimen?
### Response: Patients treated with the Bortezomib+Thalidomide+Dexamethasone (VTd) have a median Progression-Free Survival (PFS) rate of NR months, with a 95% CI of NR. |
Can you tell me the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Can you tell me the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
What’s the median PFS associated with Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: What’s the median PFS associated with Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Could you provide the median PFS of Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Could you provide the median PFS of Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
I’d like to know the median PFS of Elotuzumab+Pomalidomide+Dexamethasone (EPd). | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: I’d like to know the median PFS of Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Do you have information on the median PFS of Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Do you have information on the median PFS of Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
What is the median progression-free survival (PFS) for Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: What is the median progression-free survival (PFS) for Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Can you inform me about the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Can you inform me about the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
I’m interested in the median PFS of Elotuzumab+Pomalidomide+Dexamethasone (EPd). | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: I’m interested in the median PFS of Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Could you tell me the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Could you tell me the median PFS for Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
What is the median PFS rate for Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: What is the median PFS rate for Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
What is the median PFS rate in patients who have undergone Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: What is the median PFS rate in patients who have undergone Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
What’s the median PFS rate for patients receiving Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: What’s the median PFS rate for patients receiving Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Could you provide the median Progression-Free Survival rate for patients treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
What is the median rate of Progression-Free Survival in patients who have been treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Can you inform me about the median PFS rate in patients that were treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
What is the median PFS rate for patients that have undergone Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: What is the median PFS rate for patients that have undergone Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Could you tell me the median Progression-Free Survival rate for patients who received Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
What’s the median rate of PFS in patients treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: What’s the median rate of PFS in patients treated with Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Can you share the median Progression-Free Survival rate in patients who have received Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 10.3 months, with a 95% CI of (5.6, NE). |
Can you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Can you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
What’s the median PFS associated with Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: What’s the median PFS associated with Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Could you provide the median PFS of Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Could you provide the median PFS of Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
I’d like to know the median PFS of Pomalidomide+Dexamethasone (Pd). | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: I’d like to know the median PFS of Pomalidomide+Dexamethasone (Pd).
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Do you have information on the median PFS of Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Do you have information on the median PFS of Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: What is the median progression-free survival (PFS) for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Can you inform me about the median PFS for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Can you inform me about the median PFS for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
I’m interested in the median PFS of Pomalidomide+Dexamethasone (Pd). | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: I’m interested in the median PFS of Pomalidomide+Dexamethasone (Pd).
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Could you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Could you tell me the median PFS for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
What is the median PFS rate for Pomalidomide+Dexamethasone (Pd)? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: What is the median PFS rate for Pomalidomide+Dexamethasone (Pd)?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: What is the median PFS rate in patients who have undergone Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
What’s the median PFS rate for patients receiving Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: What’s the median PFS rate for patients receiving Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
What is the median PFS rate for patients that have undergone Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: What is the median PFS rate for patients that have undergone Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
What’s the median rate of PFS in patients treated with Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: What’s the median rate of PFS in patients treated with Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Dexamethasone (Pd) regimen? | Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Pomalidomide+Dexamethasone (Pd) regimen?
### Response: Patients treated with the Pomalidomide+Dexamethasone (Pd) have a median Progression-Free Survival (PFS) rate of 4.7 months, with a 95% CI of (2.8, 7.2). |
Can you tell me the median PFS for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Can you tell me the median PFS for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
What’s the median PFS associated with Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: What’s the median PFS associated with Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Could you provide the median PFS of Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Could you provide the median PFS of Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
I’d like to know the median PFS of Melflufen+Dexamethasone. | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: I’d like to know the median PFS of Melflufen+Dexamethasone.
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Do you have information on the median PFS of Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Do you have information on the median PFS of Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
What is the median progression-free survival (PFS) for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: What is the median progression-free survival (PFS) for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Can you inform me about the median PFS for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Can you inform me about the median PFS for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
I’m interested in the median PFS of Melflufen+Dexamethasone. | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: I’m interested in the median PFS of Melflufen+Dexamethasone.
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Could you tell me the median PFS for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: Could you tell me the median PFS for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
What is the median PFS rate for Melflufen+Dexamethasone? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: What is the median PFS rate for Melflufen+Dexamethasone?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
What is the median PFS rate in patients who have undergone Melflufen+Dexamethasone regimen? | Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). | ### Instruction: What is the median PFS rate in patients who have undergone Melflufen+Dexamethasone regimen?
### Response: Patients treated with the Melflufen+Dexamethasone have a median Progression-Free Survival (PFS) rate of 4.2 months, with a 95% CI of (3.4, 4.9). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.